Blood/ematology News

Bristol-Myers Squibb And Pfizer Initiate New Study In The Apixaban Phase 3 Clinical Trial Program

Mon, 23 Jun 2008 10:40:05 GMT

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced the start of a new Phase 3 clinical trial to assess the effect of apixaban in patients with venous thromboembolism (VTE), a potentially fatal disease process that begins with blood clots in the leg veins or lungs.

Full text

New Meta-Analysis Confirms Safety Profile For NeoRecormon In Treating Anaemia In Cancer Patients

Mon, 23 Jun 2008 10:40:04 GMT

Data Published in the British Journal of Cancer Reports That NeoRecormon use has no Negative Impact on Overall Survival or Tumour Progression A new meta-analysis of all 12 prospective, randomised, controlled studies in 2, 301 cancer patients shows that treating anaemia with NeoRecormon(R) (epoetin beta) has no negative impact on survival, tumour progression or deaths caused by blood clots, when used within its approved indications (1).

Full text

The Prescribing Of Blood Thinning Drugs Can Be Carried Out Equally Safely By Computers And Medical Experts

Sun, 22 Jun 2008 07:20:03 GMT

The largest ever study into the administration of blood thinning drugs, principally Warfarin, has concluded that dosages calculated by computer are at least as safe and reliable as those provided by expert medical professionals.

Full text

Revolade reg; eltrombopag Data Presented At EHA: Updated Data For EXTEND Plus New Data For REPEAT And DELPHI Studies

Sat, 21 Jun 2008 04:00:03 GMT

GlaxoSmithKline announced data on the long-term safety and efficacy of its investigational drug Revolade (eltrombopag) for the treatment of chronic idiopathic thrombocytopenic purpura (ITP).

Full text

REVLIMID R Data For Newly Diagnosed Multiple Myeloma Reported At A Satellite Symposium During The 13th European Hematology Association Congress

Fri, 20 Jun 2008 00:00:07 GMT

Data from the ECOG E4A03 and SWOG 0232 studies were reported at a Satellite Symposium and showed that newly diagnosed multiple myeloma patients who are eligible for a transplant, obtain better outcomes when treated with REVLIMID (lenalidomide) plus dexamethasone.

Full text

Revolade reg; Eltrombopag Data Presented At EHA: Updated Data For Extend Plus New Data For Repeat And Delphi Studies

Wed, 18 Jun 2008 20:40:06 GMT

GlaxoSmithKline has announced data on the long-term safety and efficacy of its investigational drug Revolade (eltrombopag) for the treatment of chronic idiopathic thrombocytopenic purpura (ITP).

Full text

Life-Saving Study Into Sepsis

Wed, 18 Jun 2008 20:40:05 GMT

Each year over a million people suffer from sepsis, a condition caused by an infection spreading through the body.

Full text

Soliris reg; Improved Fatigue Independent Of Changes In Anemia In Patients With PNH By Controlling Hemolysis

Wed, 18 Jun 2008 20:40:05 GMT

Soliris (eculizumab) therapy improved the often disabling fatigue experienced by patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH) independent of improvements in anemia, according to data presented at the European Hematology Association (EHA) 13th Congress in Copenhagen.

Full text

ARYx Therapeutics Inc. Commences Phase 2 3 Clinical Trial On Oral Anticoagulant Agent ATI-5923

Wed, 18 Jun 2008 20:40:04 GMT

ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced it has commenced enrollment in a Phase 2/3 clinical trial comparing its oral anticoagulation therapy, ATI-5923, against the leading anticoagulant agent, warfarin.

Full text

Doctors Underuse Effective Treatment For Sickle Cell Anemia

Wed, 18 Jun 2008 20:40:03 GMT

Uncertainties about proper use and possible long-term effects of hydroxyurea in the treatment of sickle cell anemia may be wrongly influencing doctors to avoid prescribing it to those in serious need, according to results of a literature review by specialists at Johns Hopkins.

Full text